# PALOMA (NCT04606381)

> A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

No report yet. It can be ordered.

- Indication: advanced solid malignancies

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04606381
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Neoplasms
- Interventions: Ami-LC-MD; Ami-LC; Ami-HC; Ami-HC-CF
- Enrollment: 158
- Primary outcome: Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough)
- Primary outcome: Number of Participants with Adverse Event (AE)
- Primary outcome: Number of Participants with Dose Limiting Toxicity (DLT)
- Primary outcome: Number of Participants with Clinical Laboratory Abnormalities

## Indexed commentary on PALOMA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 31 YouTube videos
- 26 posts on X
- 24 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=paloma-nct04606381

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04606381", "email": "<work email>"}; the inbox owner confirms by the emailed link.